MENU
NEWSLETTERS
MENU
SECTIONS
OTHER
CLASSIFIEDS
CONTACT US / FAQ
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

CERo Therapeutics Holdings, Inc. - Common Stock (NQ:CERO)

0.0951 UNCHANGED
Last Price Updated: 4:00 PM EDT, Oct 30, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 0
Open 0.0951
Bid (Size) 0.1167 (1)
Ask (Size) 0.1200 (461)
Prev. Close 0.0951
Today's Range 0.0951 - 0.0951
52wk Range 0.0951 - 70.00
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
CERo Therapeutics Provides Clinical Update on Phase 1 Trial of CER-1236 in AML (CertainT-1) Highlighting Key Safety Data and Platelet Transfusion–Free Interval Observed in a Patient with Myelodysplastic Syndrome/AML
From CERo Therapeutics Holdings, Inc.
Via GlobeNewswire
News headline image
CERo Therapeutics Provides Clinical Update on Phase 1 Clinical Trial of CER-1236 in AML (CertainT-1)
From CERo Therapeutics Holdings, Inc.
Via GlobeNewswire

Performance

YTD
N/A
N/A
1 Month
N/A
N/A
3 Month
-97.1%
-97.1%
6 Month
-98.9%
-98.9%
1 Year
-99.8%
-99.8%

More News

Read More
News headline image
CERo Therapeutics Announces Trading on OTCQB Market
From CERo Therapeutics Holdings, Inc.
Via GlobeNewswire
CERo Therapeutics Gets Fast Track Designation For Experimental Cancer Drug, But Stock Tumbles – Here’s What Happened ↗
Via Stocktwits
News headline image
CERo Therapeutics Initiates Second Cohort of Phase 1 Clinical Trial of CER-1236 in AML with Patient Receiving Significant Increase in Dosing
From CERo Therapeutics Holdings, Inc.
Via GlobeNewswire
News headline image
CERo Therapeutics to Present Data at the Society for Immunotherapy of Cancer Conference Highlighting Lead Compound CER-1236 Sustained Cell Expansion and Cytokine Response
From CERo Therapeutics Holdings, Inc.
Via GlobeNewswire
News headline image
CERo Therapeutics Announces Listing on OTC Markets
From CERo Therapeutics Holdings, Inc.
Via GlobeNewswire
News headline image
Stay updated with the stocks that are on the move in today's after-hours session. ↗
Via Chartmill
News headline image
Top movers in Thursday's after hours session ↗
Via Chartmill
News headline image
12 Health Care Stocks Moving In Thursday's Intraday Session ↗
Via Benzinga
News headline image
Nasdaq Falls Over 1%; Alphabet Posts Upbeat Earnings ↗
Via Benzinga
News headline image
12 Health Care Stocks Moving In Thursday's Pre-Market Session ↗
Via Benzinga
News headline image
Why Alphabet Shares Are Trading Higher By Around 8%; Here Are 20 Stocks Moving Premarket ↗
Via Benzinga
News headline image
CERo Therapeutics Announces Receipt of Nasdaq Panel Determination
From CERo Therapeutics Holdings, Inc.
Via GlobeNewswire
News headline image
CERo Therapeutics Announces Third Dose for Patient in Phase 1 Clinical Trial of CER-1236 in AML
From CERo Therapeutics Holdings, Inc.
Via GlobeNewswire
News headline image
CERo Therapeutics to Participate in Stem Cell Therapy Panel at the Maxim Growth Summit 2025
From CERo Therapeutics Holdings, Inc.
Via GlobeNewswire
News headline image
CERo Therapeutics Announces Completion of First Cohort of Phase 1 Clinical Trial of CER-1236 in AML
From CERo Therapeutics Holdings, Inc.
Via GlobeNewswire
News headline image
CERo Therapeutics Progresses Phase 1 CER-1236 AML Trial with Dosing of Third Patient in Initial Dose Cohort
From CERo Therapeutics Holdings, Inc.
Via GlobeNewswire
News headline image
Top 3 Health Care Stocks You'll Regret Missing In Q3 ↗
Via Benzinga
News headline image
CERo Therapeutics Receives Notice of Allowance from U.S. Patent and Trade Office on Composition of Matter and Method of Use for CER-1236 in Cancer with Expected Protection Through 2041
From CERo Therapeutics Holdings, Inc.
Via GlobeNewswire
News headline image
12 Health Care Stocks Moving In Monday's Intraday Session ↗
Via Benzinga
News headline image
The trading volume of these stocks is deviating from the norm in today's session. ↗
Via Chartmill
News headline image
CERo Therapeutics Announces Dose Intensification in Phase 1 Study of CER-1236 in Acute Myeloid Leukemia
From CERo Therapeutics Holdings, Inc.
Via GlobeNewswire
News headline image
12 Health Care Stocks Moving In Friday's Pre-Market Session ↗
Via Benzinga
News headline image
CERo Therapeutics Receives FDA Fast Track Designation for CER-1236 in Acute Myeloid Leukemia (AML)
From CERo Therapeutics Holdings, Inc.
Via GlobeNewswire

Frequently Asked Questions

Is CERo Therapeutics Holdings, Inc. - Common Stock publicly traded?
Yes, CERo Therapeutics Holdings, Inc. - Common Stock is publicly traded.
What exchange does CERo Therapeutics Holdings, Inc. - Common Stock trade on?
CERo Therapeutics Holdings, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for CERo Therapeutics Holdings, Inc. - Common Stock?
The ticker symbol for CERo Therapeutics Holdings, Inc. - Common Stock is CERO on the Nasdaq Stock Market
What is the current price of CERo Therapeutics Holdings, Inc. - Common Stock?
The current price of CERo Therapeutics Holdings, Inc. - Common Stock is 0.0951
When was CERo Therapeutics Holdings, Inc. - Common Stock last traded?
The last trade of CERo Therapeutics Holdings, Inc. - Common Stock was at 10/30/25 04:00 PM ET
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.
TOP
Email a Story